LOS ANGELES--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC) announced today that Dr. Nabil Dib presented interim, 6 month safety and dosage data for ACT’s Myoblast Phase I(b) Program at TCT 2007 - the Transcatheter Cardiovascular Therapeutic Conference and Exposition, in Washington D.C. from October 20-25, 2007. TCT is one of the leading conferences for the field of interventional cardiology. The interim data showed myoblast safety, with no evidence for increased risk of arrhythmia. The safety data presented by Dr. Dib distinguish the ACT Myoblast Program, which in contrast to other clinical programs does not require the use anti-arrhythmia medications and/or an implanted defibrillator device.
